How to Price Weight‑Loss Programs in Brazil

Executive summary

Clinics that move from one‑off visits to monitored programs can charge more confidently, retain longer, and generate more cash.

Over the past few years, weight‑loss offerings in Brazil have evolved from isolated nutrition consults into a robust, segmented, and increasingly sophisticated market. And as in every growing sector, the central question is: how much does it cost to lose weight?

The answer isn’t simple—because price is more than a number on paper. It depends on who is buying, what is delivered, and, above all, how the service positions itself. Observational data from programs that operate with monitoring and active triage suggest material operational gains: on average, up to ~50% higher cash generation, ~25% team efficiency gains, and ~3x higher retention when engagement is built early in treatment (EW2Health/Sinque observational data, 2024–2026; see references).

Brazil’s benchmark: four archetypes and what they charge

Brazil’s market clusters into four archetypes with typical ranges from R$150–250/month to >R$10,000 per package.

An exploratory mapping by EW2Health charted the main price bands and revealed a highly segmented landscape. Offers range from R$40 consults on popular discount platforms such as Cartão de TODOS to exclusive medical programs that cost tens of thousands of reais—with extreme VIP cases reported up to R$150,000, including renowned physicians and private in‑home cooks.

• Accessible / Inclusive
• Typical range: single visits for R$150–250; 3–6‑month bundles for R$500–1,050.
• Deliverables: one‑off consults; meal plan; online groups.
• Duration: 1 to 6 months.
• Medication: usually excluded (guidance/referral).
• Payment: short installments; cash discounts.
• Competitive / Fair
• Typical range: R$700–1,500/month (monthly/quarterly subscription).
• Deliverables: scheduled consults; coaching; basic monitoring (app/scale); monthly goals; progress indicators.
• Duration: 3–6 months (renewable).
• Medication: outside the bundle (pass‑through or guidance).
• Payment: card/PIX; 3x interest‑free is common.
• Premium / Exclusive
• Typical range: R$1,900–10,000 per program; bespoke cases up to R$150,000.
• Deliverables: multidisciplinary team; on‑demand contact; advanced testing and tech; concierge.
• Duration: 3–12 months (or bespoke programs).
• Medication: may include logistics; drug cost often separate.
• Payment: contracts; extended installments.
• Flexible / Patient‑Centered
• Typical range: modular by profile; mixes subscription + add‑on packages.
• Deliverables: personalized tracks; variable intensity; upgrade/downgrade paths.
• Duration: 3, 6, or 12 months (with pauses/reviews).
• Medication: always a separate line item or at cost.
• Payment: clear rules for switching and interruption.

Methodology and caveat: exploratory mapping based on public offers, operator conversations, and market observation in H1 2026; indicative values vary by city and service mix. Validate locally before publishing prices.

How programs charge: models and trade‑offs

Clinics that move from one‑off consults to formal subscription programs gain revenue predictability and reduce churn.

Useful definitions:

• A one‑off consult is payment per clinical act with no program structure.
• A subscription is a recurring (monthly/quarterly) charge that grants access to a set of deliverables.
• A GLP‑1 bundle is when the clinic combines service + medication in one package (or passes through the medication with clear terms).
• Pay‑as‑you‑go is unit pricing (e.g., sessions, tests, days of metabolic hoteling).

Operational pros and cons:

• One‑off consult
• Pros: simple; no future obligations.
• Cons: volatile revenue; higher abandonment risk; hard capacity planning.
• Subscription (monthly/quarterly)
• Pros: predictability; supports follow‑up; dilutes CAC; enables scalable monitoring and triage.
• Cons: requires clear deliverables and SLAs; churn and delinquency management.
• GLP‑1 bundle
• Pros: convenience for patients; “complete solution” narrative.
• Cons: high and volatile COGS; margin compression risk; better to separate drug price with a therapy‑management fee.
• Pay‑as‑you‑go
• Pros: unit transparency; good for ancillary services.
• Cons: encourages irregular use; weakly aligned with long‑term outcomes.

GLP‑1 changed the rules: from consults to continuous programs

GLP‑1 medications are incretin‑based therapies that increase satiety and slow gastric emptying, producing 15–20% weight loss over 68–72 weeks in trials, but they require continuity and behavioral support.

• In STEP 1 (semaglutide 2.4 mg), adults with obesity lost ~14.9% at 68 weeks versus ~2.4% with placebo.
• In SURMOUNT‑1 (tirzepatide), mean loss reached ~20.9% at 72 weeks at higher doses.
• In STEP 4 (withdrawal), stopping the drug led to substantial weight regain, underscoring maintenance needs.
• In real‑world use, 12‑month persistence is challenging, and early drop‑off reduces outcomes and wastes acquisition spend.

This shifts value from the “act” to the “program”: without continuous engagement and monitoring, pharmacologic efficacy does not convert into durable results—and pricing that ignores this dynamic underestimates churn and overestimates LTV.

A quick framework and calculator: from list price to sustainable price

A sustainable price is one where gross‑margin LTV covers at least 3x CAC, with buffer for delinquency and seasonality.

• Practical formulas
• LTV (revenue) ≈ Monthly ARPU / Monthly churn.
• LTV (margin) ≈ (Monthly ARPU × Gross margin) / Monthly churn.
• Rule of thumb: (LTV margin) ≥ 3 × CAC.
• ARPU is average monthly fee actually paid (after discounts).
• Monthly churn is the rate of program cancellation/exit per month.
• Example 1 — without engagement infrastructure
• CAC: R$600; monthly fee: R$450; gross margin: 55%; churn: 12%/month.
• LTV (margin) ≈ (450 × 0.55) / 0.12 = R$2,062.
• LTV/CAC ≈ 3.4x (acceptable, limited shock absorption).
• Example 2 — with monitoring and triage (lower churn, higher ARPU)
• CAC: R$600; monthly fee: R$500; gross margin: 55%; churn: 4%/month.
• LTV (margin) ≈ (500 × 0.55) / 0.04 = R$6,875.
• LTV/CAC ≈ 11.5x (robust; allows higher acquisition investment or price reductions without sacrificing margin).
• Be careful with bundles that include medication
• GLP‑1 drug cost can easily exceed the subscription—embedding the drug without pass‑through tends to collapse margins.
• Good practice: separate service price + pharmacotherapy management fee; add an adjustment clause when the drug changes.
• Essential accounting step
• Separate clinical COGS (team time, tests, technology) from pharmaceutical COGS (drug, supplies); calculate margin per line.

Behavioral infrastructure lifts retention, ARPU, and margin

Daily behavioral monitoring—not just biomarkers—reduces abandonment, flags risk early, and improves a program’s unit economics.

The operational problem is well known: self‑weighing tends to drop over time; long gaps correlate with regain; and many patients avoid negative feedback (the “ostrich effect”). Programs that make monitoring emotionally safe and translate day‑to‑day fluctuation into trend can protect the habit and act before no‑shows.

Evidence and data that support pricing and subscriptions:

• Self‑weighing declines substantially over longer programs; intervals >30 days raise regain risk (2013–2014 literature; see references).
• In EW2Health/Sinque observational data (2024–2026):
• Building the habit of weighing ≥4 times/week for the first 8 weeks is associated with ~9x lower risk of dropping out.
• Patients with early engagement stay ~3x longer.
• Triage and right‑patient focus increase team efficiency by ~25%.
• Together, these effects translate into ~50% more cash generation for GLP‑1 programs.
• Monitoring frequency associates with ~4x higher odds of losing ≥5% at 6 months.

Methodological note: results above are observational (association, not causation) and vary by context. Still, they explain why recurring pricing is defensible when a program includes monitoring and predictive triage—lower churn justifies competitive ARPU without sacrificing margin.

The patient’s wallet also changed: access, installments, and value narrative

The cost of maintaining a healthy diet in Brazil has risen, pressuring household budgets and adherence to programs.

Recent international reports and national data indicate a real increase in the cost of a healthy diet in Brazil between 2017 and 2022. In this context, many clinics adopted:

• 3/6/12‑month plans with clear, no‑surprise installments.
• Simple rules to pause and resume the program (reduces delinquency).
• Transparency: service price separated from drug cost, when applicable.

Narrative matters: the same “microphone” costs more when it carries a story. In healthcare, price is not about consults; it is about transformation with safety, convenience, and predictability. Making progress visible—and emotionally safe—supports willingness to pay.

How to set your price in 5 steps

Clinics that follow a simple playbook avoid anchoring traps and defend margins better.

1. Define your archetype and target segment

• Accessible, competitive, premium, or flexible? Which problem do you solve and for whom?

1. List required and optional deliverables

• Consults, coaching, support channels, monitoring, tests. Separate the base from upgrades.

1. Model retention and true cost

• Estimate monthly churn with/without monitoring; calculate clinical COGS and, if relevant, pharmaceutical COGS (separate).

1. Choose the charging model

• Subscription as default; service and drug as distinct lines; clear policies for installments and pauses.

1. Run the sustainability calculator

• ARPU, margin, churn, and CAC. Adjust price/deliverables until margin LTV ≥ 3× CAC, with buffer for delinquency.

Conclusion

Brazil’s weight‑loss market is no longer a market of medical visits or meal plans—it is a market of continuous, outcomes‑oriented programs.

Pricing is therefore strategic positioning: being inclusive, fair, exclusive, or flexible depends less on the consult fee and more on the value story you can sustain month after month. In the GLP‑1 era, the gap between sticker price and sustainable price is called retention—and retention is built with safe monitoring, predictive triage, and attention to the right patient at the right time.

References

• Wilding JPH, et al. Once‑Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021.
• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT‑1). New England Journal of Medicine, 2022.
• Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA, 2021.
• Webb TL, Chang BPI, Benn Y. The Ostrich Problem: Motivated Avoidance of Feedback About Goal Progress. Social and Personality Psychology Compass, 2013.
• Helander EE, et al. Weight Loss by Frequent Self‑Weighing and Instant Feedback With a Smart Scale. PLOS ONE, 2014.
• Pacanowski CR, Linde JA. Self‑Weighing: Prospective Associations With Weight and Health‑Related Outcomes. Obesity, 2015.
• EW2Health/Sinque internal data (2024–2026): observational analyses of engagement, retention, triage, and economic impact in GLP‑1 programs; includes insights presented in the deck “Predictive Behavioral Analytics for Medical Weight‑Loss Clinics” (Mayo Clinic Platform: model refinement; no endorsement of outcomes).
• SOFI – The State of Food Security and Nutrition in the World 2023/2024, FAO/PAHO (reference for diet costs; verify exact value and base year for Brazil).
• Real‑world persistence/adherence to anti‑obesity pharmacotherapy (2023–2024)—see reviews in Obesity and JAMA Health Forum for 12‑month discontinuation rates (verify the latest rates for GLP‑1 in Brazil).